Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 3 | 0 | 2 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 7 | 2 | 3 | 0 | 1 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 1 |
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $111.06, a high estimate of $168.00, and a low estimate of $65.00. Surpassing the previous average price target of $89.40, the current average has increased by 24.23%.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst...
Login or create a forever free account to read this news
Sign up/Log in